Conflicts of Interest, Institutional Corruption, and Pharma: An Agenda for Reform

Conflicts of Interest, Institutional Corruption, and Pharma: An Agenda for Reform

When physicians' conflicts of interest arise from ties with drug firms, we should shift our focus to the pharmaceutical industry and improper dependencies that cause institutional corruption. This article analyzes eight forms of improper dependencies on pharma and proposes reforms.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of law, medicine & ethics medicine & ethics, 2012-09, Vol.40 (3), p.511-522
1. Verfasser: Rodwin, Marc A.
Format: Artikel
Sprache:eng
Schlagworte:
Clinical trials
Company business management
Conflict of Interest - economics
Conflict of Interest - legislation & jurisprudence
Conflict of interests (Agency)
Conflict of interests (business)
Conflicts of interest
Corporate corruption
Corporations
Corruption
Disclosure
Drug and Narcotic Control
Drug Industry - economics
Drug Industry - ethics
Drug Industry - legislation & jurisprudence
Drug use
Drugs
Economic incentives
Education, Medical, Continuing
Ethical aspects
Ethics
Ethics, Institutional
FDA approval
Fiduciary responsibility
Financing, Organized - ethics
Financing, Organized - legislation & jurisprudence
Health technology assessment
Humans
Incentives
Influence
Information Dissemination
Law
Management
Medical education
Medicine
Monetary incentives
Organizational Culture
Patent law
Patients
Pharmaceutical industry
Pharmaceutical research
Physicians
Prescription drugs
Public health
Public Policy
R&D
Research & development
Research Support as Topic
Social norms
Society
Subsidies
United States
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:When physicians' conflicts of interest arise from ties with drug firms, we should shift our focus to the pharmaceutical industry and improper dependencies that cause institutional corruption. This article analyzes eight forms of improper dependencies on pharma and proposes reforms.
ISSN:1073-1105
1748-720X
DOI:10.1111/j.1748-720X.2012.00683.x